Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Condition Vasoregulation Function Endothelium in Patients With Chronic Myeloid Leukemia (CML) Getting Tyrosine Kinase Inhibitor (TKI) II Generation Bosutinib

NCT05682924 is registered in ClinicalTrials.gov with Samara State Medical University as lead sponsor.

NCT NCT05682924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05682924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Condition Vasoregulation Function Endothelium in Patients With Chronic Myeloid Leukemia (CML) Getting Tyrosine Kinase Inhibitor (TKI) II Generation Bosutinib
Lead sponsor
Samara State Medical University
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2022
Completion date
September 15, 2025
Enrollment
105 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukaemia